

## AUTHOR INDEX

### VOLUME 25

Ackerman, Bruce H., 785  
 Ackers, Irene, 579  
 Actor, P., 373  
 Actor, Paul, 694  
 Adejuigbe, Olusanya, 497  
 Adkinson, N. Franklin, Jr., 93  
 Ahmed, S. Masud, 643  
 Akhter, S. Q., 643  
 Albritton, William L., 187, 296  
 Alford, Robert H., 405  
 Anderson, Burt, 296  
 Andreana, Augusto, 182  
 Andrews, J. M., 612  
 Andritz, Mary H., 33  
 Angehrn, Peter, 607  
 Apolloni, E., 760  
 Arbeter, A. M., 417  
 Arceneaux, Jean E. L., 650  
 Arcey, Sergio M., 16  
 Arndt, Kenneth A., 553  
 Aronoff, George R., 513  
 Aronoff, Stephen C., 279  
 Arosio, E., 760  
 Asahi, Yoshinari, 131  
 Ash, Ronald J., 443  
 Assael, Baroukh M., 395  
 Auerbach, Jeffrey I., 622  
 Auger, François, 662  
 Austin, Thomas W., 455  
 Ayers, L. W., 633  
 Ayers, Leona W., 669  
 Aytron, John, 78  
 Azegami, Masao, 146

Baba, Masanori, 515  
 Baker-Zander, Sharon A., 390  
 Ballard, James O., 153  
 Baltch, Aldona L., 33, 488  
 Bannatyne, Robert M., 537  
 Barge, Janine, 168  
 Barlam, Tamar, 529  
 Barnes, Scott G., 153  
 Baron, Ellen J., 781  
 Baron, Jody L., 646  
 Baron, Samuel, 646  
 Barrueco, M., 458  
 Barry, A. L., 633  
 Barry, Artur L., 392, 669, 710, 775  
 Bartus, Henry R., 622  
 Barza, Michael, 655  
 Baxter, Heather, 306  
 Bayer, Arnold S., 725  
 Beaulieu, Bernard B., Jr., 65  
 Bedows, Elliott, 719  
 Beggs, William H., 316  
 Beight, Douglas W., 443  
 Belshiem, Judy, 179  
 Benoni, G., 760  
 Berens, Randolph L., 292  
 Berliner, Daniel, 7  
 Berman, Steven J., 438  
 Bianchi, P., 666  
 Biddle, James, 296  
 Bieth, Gilda, 289  
 Blase, David K., 513  
 Blevins, Roger D., 603  
 Blok-Perkowska, Danuta, 134  
 Blomqvist, Charlotte, 179  
 Blumer, Jeffrey L., 579  
 Bondi, Joseph V., 238

Bongaerts, Ger P. A., 234  
 Borner, K., 105  
 Borobio, M. Victoria, 342  
 Borowski, E., 772  
 Borsa, F., 638  
 Bosso, John A., 630  
 Boutwell, M. E., 650  
 Bouzos, John, 534  
 Bright, Gene M., 113  
 Brion, Nils, 168  
 Brook, Itzhak, 71  
 Brown, Daniel R., 422  
 Brown, Douglas, 286  
 Brown, Timothy H., 405  
 Brumfitt, W., 276  
 Bryan, C. S., 37  
 Bryan, L. E., 382, 747  
 Buesing, Mary A., 283  
 Butler, Thomas, 643  
 Buu-Hoi, Annie, 289  
 Byers, B. R., 650

Cabezudo, Ignacio, 4  
 Cable, Douglas C., 258  
 Campbell, Gwendolyn S., 205  
 Campos, Jose, 706  
 Campos, Joseph M., 327  
 Carbon, Claude, 168, 618  
 Cardinal, J. R., 10  
 Carr, Douglas, 539  
 Carter, Walker T., 162  
 Casalino, M., 499  
 Catlin, B. Wesley, 676  
 Chan Lee, Huei, 146  
 Chau, Nguyen Phong, 618  
 Cheung, Rose, 537  
 Chiemchanya, Surang, 273  
 Chin, Nai-Xun, 319, 687  
 Chopra, Ian, 446  
 Chou, Sunwen, 25  
 Cohn, Naomi K., 292  
 Coleman, William G., Jr., 539  
 Collins, Shirley H., 301  
 Comanducci, A., 499  
 Congeni, Blaise L., 40  
 Conroy, Joseph V., 33  
 Contrepose, Alain, 168, 618  
 Coolbaugh, James C., 71  
 Coppenhaver, Dorian H., 646  
 Correia, Ricardo A., 653  
 Crooke, Stanley T., 622  
 Crossley, Kent B., 532  
 Crumpacker, Clyde S., 247, 553  
 Culbert, Steve, 62

Daneshmend, Tawfique K., 1  
 Davidson, Bruce A., 719  
 Davies, Mary-Ellen M., 238  
 Davis, Donald R., 20  
 De Broe, Marc E., 783  
 De Clercq, Erik, 566  
 DeClercq, Erik, 515  
 DeGirolami, P., 401  
 Deneer, Harry G., 187  
 Denoya, Claudio D., 659  
 Devlin, Richard G., 358  
 Devos, J., 764  
 Dewsnup, Daniel H., 165  
 Dilillo, Mariantonia, 182  
 Diven, Warren, 473  
 Dominguez-Gil, A., 458

Dotzla, Joe E., 216  
 Dromer, Françoise, 168  
 Dubois, Catherine, 168  
 Dubreuil, L., 764  
 Dunn, George L., 694  
 Dworzack, David L., 494  
 Dylewski, Joe S., 25

East, Donald S., 83  
 Eby, George A., 20  
 Echo, Roger M., 336  
 Egbert, Peter R., 25  
 Eisenstadt, Rosalee, 725  
 Elion, Gertrude B., 507  
 Eliopoulos, G. M., 331, 401  
 Eliopoulos, George M., 398  
 Elvers, A., 105  
 Ene, Mokelu D., 1  
 Eng, Robert H. K., 510  
 English, A. R., 118  
 English, Arthur R., 113, 226, 599  
 Eppstein, Deborah A., 563

Fadl-Allah, Nora, 375  
 Fainstein, V., 387  
 Falkinham, Joseph O., III, 137  
 Farber, Bruce F., 398  
 Fasching, Claudine E., 58, 545, 596  
 Fass, Robert J., 408  
 Field, A. Kirk, 238, 247  
 Fillastre, J. P., 638  
 Finegold, Sydney M., 162  
 Fischer, Philip R., 502  
 Fite, Laurie D., 443  
 Fliegelman, Robert M., 504  
 Fiorilli, Alessandra, 395  
 Flynn, Gary A., 443  
 Foglesong, Mark A., 216  
 Fontijne, P., 575  
 Forbes, Betty A., 491  
 Forthal, Donald N., 258  
 Fortin, Louise, 83  
 Fourillant, Jean-Bernard, 618  
 Frankel, Lawrence S., 62  
 Fraser-Smith, Elizabeth B., 563  
 Freydier, A. M., 144  
 Frongillo, R. F., 666  
 Fuchs, Peter C., 392  
 Funk, Mary L., 301  
 Furman, Phillip A., 191, 507

Gangemi, J. D., 37  
 Garcia-Tornel, Santiago, 706  
 Gardella, A., 331, 401  
 Gavan, Thomas L., 669  
 Gaynor, Michael W., 25  
 George, Karen L., 137  
 George, W. Lance, 657  
 Geratz, J. Dieter, 582  
 Gerding, Dale N., 58, 545, 560  
 Gerlach, E. H., 633, 669  
 Gervós, M. Santiago, 458  
 Giamarellou, Helen, 534  
 Gill, Charles J., 327  
 Gill, M. John, 476  
 Gille, Y., 144  
 Girard, A. E., 118  
 Girard, Dennis, 599  
 Giuliano, Rubén A., 783  
 Givan, Katherine F., 455

Glasser, Lynne A., 510  
 Glette, Johan, 354  
 Gnarpe, Håkan, 179  
 Godefroy, Isabelle, 168  
 Godfrey, A. J., 382  
 Goessens, Wil H. F., 575  
 Goldman, Peter, 65  
 Gombert, Myles E., 510  
 Gooch, W. Manford, III, 502  
 Goodman, Larry J., 504  
 Gootz, Thomas D., 591  
 Gordon, Y. Jerold, 522  
 Goto, Sachiko, 98  
 Gotoh, Akira, 754  
 Goueffion, Y., 463  
 Grappel, Sarah F., 694  
 Greenman, Richard L., 16  
 Griffin, Paul E., 33  
 Gropen, Toby I., 522  
 Grossman, Dena M., 690  
 Gruff, Howard, 137  
 Guay, David R., 306  
 Guenther, Sharon H., 4  
 Guerrant, Richard L., 653  
 Guterman, Deborah A., 16  
 Guymon, L. F., 767

Halcomb, William W., 20  
 Hall, Dennis, 571  
 Hall, Michael J., 607  
 Haller, Ingo, 125  
 Halstenson, C. E., 128  
 Halstenson, Charles E., 433, 603  
 Hamilton-Miller, J. M. T., 276  
 Hammer, Mark C., 33  
 Hansen, Alfred R., 301  
 Hansen, Chad S., 301  
 Hantz, O., 242  
 Harcus, Jane L., 571  
 Harding, Stuart M., 78, 344  
 Harris, Betty, 162  
 Harris, Cynthia, 560  
 Harrison, Lester I., 301  
 Hashizume, Terutaka, 148  
 Haskell, Suzanne L., 599  
 Hastie, Annette T., 673  
 Hayden, Frederick G., 53  
 Hector, Richard F., 596  
 Heessen, Frans W. A., 123  
 Herbst, John J., 630  
 Hersch, Evan M., 366  
 Hewlett, Erik L., 571  
 Higgins, Michael L., 673  
 Hindler, Janet A., 781  
 Hirata, Takahiro, 148, 348  
 Hoeprich, Paul D., 339  
 Holmes, King K., 390  
 Hooper, David C., 586  
 Hopen, Gunnar, 354  
 Hopfer, R. L., 387  
 Hopfer, Roy L., 366  
 Horaud, Thea, 289  
 Hughes, Carolyn E., 560, 596  
 Humbert, G., 638  
 Hunaiti, Abdelrahim A., 173

Ikeda, Chieko, 221  
 Inaba, Hitoshi, 88  
 Inoue, Hiroshi, 146  
 Inoue, Matsuhisa, 362

Isono, Midori, 131  
 Ito, Masahiko, 515

Jackson, David B., 591  
 Jacobs, Michael R., 527  
 Jacoby, Irving, 626  
 Jacyk, William R., 306  
 Jakas, Dalia R., 694  
 James, Philip R., 735  
 Jenkin, H. M., 772  
 Johnson, Elizabeth M., 1  
 Johnson, Jonas, 473  
 Johnson, Randall K., 622  
 Johnson, Steven R., 296  
 Johnston, Ralph W., 205  
 Jones, R. N., 633  
 Jones, Ronald N., 392, 669, 710, 775  
 Jordan, A. B., 37  
 Jorgensen, James H., 283  
 Juliano, R. L., 387  
 Juliano, Rudolph L., 366

Kabir, Iqbal, 643  
 Kamimura, Toshiaki, 98  
 Kanzaki, Masako, 385  
 Kaplan, Raymond L., 504  
 Katz, Ehud, 195  
 Katz, W., 253  
 Keane, W. F., 128  
 Keane, William F., 433  
 Kern, Earl R., 553  
 Kesado, Tadataka, 131  
 Kim, H., 45  
 King, John W., 770  
 Kingsbury, W. D., 373  
 Kirkpatrick, James, 7  
 Klein, Robert S., 292  
 Klinger, Jeffrey D., 279  
 Knaus, Edward E., 476  
 Knight, Paul R., 719  
 Knight, Vernon, 729  
 Kobasa, William D., 683  
 Koeppe, P., 105  
 Kojo, Hitoshi, 98  
 Kolattukudy, Pappachan E., 173  
 Konno, Masatoshi, 754  
 Konopińska, Danuta, 134  
 Kosuzume, Hiroshi, 88  
 Koyama, Masaru, 221  
 Kramer, Michael J., 729  
 Kramer, William G., 62  
 Kreeft, John H., 83  
 Kueppers, Friedrich, 673  
 Kunz, Samuel, 311  
 Kuroki, Tohru, 146  
 Kuwahara, Shogo, 98  
 Kwan, S., 382

Labthavikul, Pornpen, 687  
 Lacroix, Jean-Michel, 662  
 Lambe, Catherine U., 191  
 Lamotte, François, 662  
 Larsson, A., 524  
 Lastra, C. Fernandez, 458  
 Lawee, David, 455  
 Lechi, A., 760  
 Lefler, Eli, 450  
 Leguy, F., 638  
 Leive, Loretta, 539  
 Lentino, Joseph R., 778  
 Leroy, A., 638  
 Levi, Joe U., 358  
 Levison, Matthew E., 683

Lewis, John C., 380  
 Lewis, Michael R., 422  
 Li, Edwin L. F., 455  
 Lin, C., 45  
 Lind, I., 767  
 Lipsky, James J., 380  
 Liverelli, Thomas J., 247  
 Livermore, David M., 268  
 Lloyd, William J., 607  
 Lode, H., 105  
 Lolekha, Somsak, 273  
 Lopez-Berestein, G., 387  
 Lopez-Berestein, Gabriel, 366  
 Lorian, Victor, 311  
 Lowy, Franklin D., 375  
 Luft, Friedrich C., 513  
 Lukehart, Shelia A., 390  
 Lundbäck, Annika, 179  
 Lynch, J. E., 118  
 Lyon, James, 473

Maclean, Ian W., 187  
 Mader, Jon T., 139  
 Mageau, Richard P., 205  
 Maimone, F., 499  
 Malewicz, B., 772  
 Mandel, Neil, 109  
 Manian, Albert A., 571  
 Margalith, Eva., 195  
 Maríño, E. L., 458  
 Marino, John, 527  
 Marks, Melvin I., 212  
 Marlowe, Steve, 553  
 Marr, J. Joseph, 292  
 Marsh, Y. Vivienne, 563  
 Martin, Albert R., 626  
 Martinez, Octavio V., 358  
 Maruyama, Tsutomu, 385  
 Maskell, Jeffrey P., 268  
 Matsen, John M., 630  
 Matsui, Hidefumi, 221  
 Matsumoto, Yoshiimi, 98  
 Matthews, Thomas R., 563  
 Mattie, H., 263  
 Matzke, G. R., 128  
 Matzke, Gary R., 433, 603  
 McAnally, Thomas P., 422  
 McClatchey, Kenneth D., 491  
 McCormick, Ellen M., 336  
 McCracken, George H., Jr., 29, 427, 556  
 McFarland, James W., 226  
 McGory, Robert W., 433  
 McGuirt, Paul V., 507  
 McHugh, Gail L., 586  
 McKeough, M. B., 10  
 McKerlie, M. Louiese, 646  
 McLafferty, Martha A., 65  
 Meatherall, Robert C., 306  
 Meddens, M. J. M., 263  
 Mehta, Kapil, 366  
 Mehta, R., 387  
 Mehta, Reeta, 366  
 Mehta, R. J., 373  
 Merigan, Thomas C., 25  
 Merry, Joanne M., 339  
 Meshnick, Steven R., 286  
 Metzger, Linda S., 216  
 Michel, M. F., 575  
 Miller, Heather, 411  
 Miller, Richard L., 191  
 Miller, Wayne H., 191  
 Mills, K., 387  
 Mine, Yasuhiro, 98

Mirabelli, Christopher K., 622  
 Mitsuhashi, Susumu, 362  
 Miyakawa, Isao, 146  
 Mobley, Harry L. T., 157  
 Mochizuki, Hidenori, 88  
 Moellering, R. C., Jr., 331, 401  
 Moellering, Robert C., Jr., 398  
 Molendijk, Lucy, 234  
 Momsen, M., 772  
 Montay, G., 463  
 Moody, Julia A., 545, 560  
 Moretti, A., 666  
 Morgan, S. L., 37  
 Morgant, Catherine, 618  
 Mori, Norimasa, 146  
 Morrison, Joan O., 725  
 Muder, Robert R., 473  
 Muller, G., 281  
 Muramatsu, Masatake, 385  
 Murray, Barbara E., 398  
 Murray, Patrick R., 368  
 Muytjens, Harry L., 123  
 Muzalewski, Feliks, 134  
 Myers, Carolyn M., 579  
 Myers, William F., 690

Nagel, Arthur A., 113  
 Nakagawa, Keiichi, 221  
 Nakatsuru, Naoki, 221  
 Nelson, Donald J., 292  
 Nelson, Erica, 522  
 Nesburn, Anthony B., 522  
 Neu, Harold C., 319, 529, 687  
 Neut, C., 764  
 Nguyen, Khoi B., 455  
 Nicoletti, M., 9  
 Nierste, David M., 513  
 Niles, Ann C., 368  
 Noguchi, Takashi, 221  
 Northrop, Dexter B., 479  
 Novick, William J., Jr., 380

Ober, Robert E., 301  
 Odio, Carla, 427, 556  
 Ogilvie, Richard I., 83  
 Ohmae, Kenichi, 385  
 Ohnishi, Haruo, 88  
 Okafor, Josephine I., 413  
 Olsen, Kurt D., 29  
 Ooka, T., 242  
 Opal, Stephen, 7  
 Otto, Michael J., 566  
 Overall, James C., Jr., 553  
 Overturf, Gary D., 258

Panosian, Claire B., 655  
 Parker, Bruce C., 137  
 Parr, Thomas R., Jr., 747  
 Parrillo, Patricia, 778  
 Passarella, E., 760  
 Pasticci, M. B., 666  
 Patel, Indravadan H., 438  
 Pattison, Fred L. M., 455  
 Pattyn, Stefaan R., 518  
 Pauluzzi, S., 666  
 Pearson, Richard D., 571  
 Penn, Robert L., 770  
 Penner, Brian, 306  
 Pennington, James E., 49  
 Perea, Evelio J., 342  
 Perna, Pasquale, 182  
 Perry, Helen C., 247  
 Peters, Andre C. B., 522

Peterson, Lance R., 58, 545, 560, 596  
 Pfaller, Michael A., 368  
 Phillips, Lillian, 694  
 Pichoud, C., 242  
 Pickering, Larry K., 62  
 Pirie, Donald K., 226  
 Pitkin, Donald, 694  
 Piziak, Myron V., 7  
 Plotkin, S. A., 417  
 Pohlod, Donald J., 377  
 Pollack, Simeon, 375  
 Pollet, Dirk E., 783  
 Porter, F. D., 157  
 Portnoy, David, 455  
 Potten, Michael R., 1  
 Preblud, S. R., 417  
 Preblud, Stephen R., 327  
 Proctor, E. A., 417  
 Provost, Abraham P., 497  
 Prusoff, William H., 566  
 Pugsley, Mary P., 494  
 Pushkarskaya, Nina L., 53

Radika, Kesavan, 479  
 Rahaman, M. Mujibur, 643  
 Raimondi, M. G., 760  
 Rector, Tim M., 582  
 Reed, Michael D., 579  
 Retsema J. A., 118  
 Retsema, James A., 113, 226  
 Richardson, Malcolm D., 1  
 Ripa, S., 666  
 Rohlfing, Stephen R., 301  
 Romanowski, Barbara, 455  
 Romaru, Annette, 618  
 Romond, C., 764  
 Ronald, Allan R., 187  
 Roquet, F., 463  
 Rosano, Thomas G., 336  
 Rosen, Barry P., 157  
 Rosenberg, Martin, 622  
 Ross, Janette, 785  
 Rotschafer, John C., 785  
 Rubin, Robert H., 626  
 Ruggiero, Giuseppe, 182  
 Rusconi, Franca, 395  
 Ryder, Neil S., 483

Sabados, Joyce, 646  
 Saino, Yushi, 362  
 Sakata, Yasutaka, 29  
 Sakuma, Takashi, 742  
 Salem, Nanda G., 603  
 Samuel, John, 476  
 Sandberg, Sverre, 354  
 Sanders, Christine C., 494  
 Sanders, W. Eugene, Jr., 494  
 Sanfelius, Isabel, 706  
 Saravolatz, Louis D., 377  
 Sattler, Fred R., 153  
 Sawada, Taku, 385  
 Sawai, Tetsuo, 148, 348  
 Saxon, Barbara A., 630  
 Schaberg, Dennis R., 491  
 Scharpé, Simon L., 783  
 Schelkly, W., 118  
 Schentag, Jerome J., 201  
 Schiff, Jill B., 49  
 Schlepushkin, Anatoli N., 53  
 Schnipper, Lowell E., 553  
 Schultz, Robert W., 201  
 Schuppan, Dietrich, 301  
 Schuster, F. L., 109

Schwab, Bernard, 205  
 Sciavolino, Frank C., 113  
 Scribner, Ronald K., 212  
 Seidl, Gunther, 483  
 Selden, Robert F., 4  
 Seto, Kenji, 385  
 Shafer, W. M., 767  
 Shatzman, Allan R., 622  
 Shaw, James E., 507  
 Sherris, John C., 591  
 Shields, David S., 653  
 Shigeta, Shiro, 515  
 Shikuma, Cecilia, 258  
 Shipley, Patricia L., 653  
 Shlaes, David M., 527  
 Siegel, Scott A., 566  
 Siemsen, A. W., 438  
 Silver, Simon, 157  
 Sirinavin, Sayomporn, 273  
 Slaney, Leslie A., 187  
 Smith, C. W., 37  
 Smith, Gaylord, 286  
 Smith, Margaret C. M., 446  
 Smith, Raymond P., 33, 488  
 Sobel, J. D., 281  
 Solberg, Claus O., 354  
 Solliday, JoAnne, 532  
 Somerville, Peter J., 83  
 Sommers, De Klerk, 344  
 Sommers, H. M., 633  
 Sommers, Herbert M., 669  
 Southern, J. A., 253  
 Sparling, P. F., 767  
 Spencer, G. R., 638  
 Spruance, S. L., 10  
 Spruance, Spotswood L., 553  
 St. Clair, Marty H., 191  
 Stachowski, Michael, 778  
 Starr, S. E., 417  
 Steigbigel, Neal H., 375  
 Stern, Robert C., 579  
 Stevens, David A., 450  
 Storrs, Bruce, 502  
 Strikas, Raymond, 778  
 Stutman, Harris R., 212  
 Sugerman, A. Arthur, 93  
 Sugihara, J. G., 438  
 Sun, Chong-Son, 729  
 Sutphen, Nancy, 33  
 Sutton, J. P., 37  
 Swabb, Edward A., 93  
 Swartz, Mark D., 586  
 Swartz, Morton N., 586  
 Szoka, Francis, 655  
 Tagari, Gioula, 534  
 Takafuji, Ernest, 7  
 Takahashi, Toshio, 385  
 Tannenbaum, Charles S., 673  
 Tao, Pei-Zhen, 524  
 Taylor, Dean P., 622  
 Telesetsky, Stephanie, 539  
 Terakado, Nobuyuki, 385  
 TeStrake, Diane, 413  
 Thearle, Patricia, 473  
 Thomas, Marion L., 29, 427, 556  
 Thompson, J., 263  
 Thompson, Robert L., 4  
 Thornsberry, C., 633  
 Thornsberry, Clyde, 392, 710  
 Threlkeld, Norma, 556  
 Ti, Teow-Yee, 83  
 Tidwell, Richard R., 582  
 Tiemens, Karen M., 653  
 Tigaud, S., 144  
 Tocci, Michael J., 247  
 Tofte, Robert W., 532, 785  
 Tolokoff-Rubin, Nina E., 626  
 Tramont, Edmund, 7  
 Trenholme, Gordon M., 504  
 Trepo, C., 242  
 Trevisán, Alejandro R., 659  
 Troke, Peter F., 483  
 Trousdale, Melvin D., 522  
 Tuazon, Carmelita U., 411  
 Tung, Charlotte, 586  
 Tyrrell, D. Lorne, 476  
 Ubukata, Kimiko, 754  
 Ueno, Kazue, 131  
 Utili, Riccardo, 182  
 Vaara, M., 701  
 Valenta, J., 373  
 Van Caekenbergh, Dirk L., 518  
 Van Etta, Linda L., 58  
 van Furth, R., 263  
 Van Leeuwen, Willem B., 497  
 van Raffe, M., 575  
 Van Schalkwijk, Wim P., 497  
 Van Wyk, Marieta, 344  
 Vaxelaire, Juliane, 311  
 Velo, G. P., 760  
 Verbist, Ludo, 141, 783  
 Verhaegen, Jan, 141  
 Verpoorten, Gert A., 783  
 Viljanen, P., 701  
 Vincent, P., 144  
 Visscher, David W., 513  
 Visudhipan, Pongsakdi, 273  
 Vitvitski, L., 242  
 Vosbeck, Klaus, 735  
 Wagenvoort, Johan H. T., 497  
 Walker, David H., 582  
 Walker, Marion L., 502  
 Walker, Naomi A., 513  
 Walker, Richard I., 71  
 Warnock, David W., 1  
 Watanabe, Kunitomo, 131  
 Weinbaum, George, 673  
 Weinfeld, R. E., 438  
 Weiss, Emilio, 71  
 Welage, Lynda S., 201  
 Welch, David F., 212  
 Wenneersten, Christine, 398  
 Wenzel, Richard P., 4  
 Westmacott, Donald, 607  
 Wexler, Hannah, 162  
 Wiebe, Leonard I., 476  
 Williams, J. David, 268  
 Williams, Peter E. O., 78, 344  
 Williamson, Peter J., 1  
 Wilson, Katharine J., 139  
 Wilson, Mary E., 626  
 Wilson, Samuel Z., 729  
 Wise, R., 612  
 Wissman, Charles L., Jr., 690  
 Wolfson, John S., 586  
 Wong, E. G. C., 438  
 Woodbury, Charles, 7  
 Woods, D. R., 253  
 Wright, Charlotte A., 408  
 Wright, Donald N., 165  
 Wu, David H., 488  
 Wyde, Philip R., 729  
 Wyler, David J., 655  
 Yamaguchi, Akihito, 148, 348  
 Yamashita, Naoko, 754  
 Yamashita, Toyoko S., 579  
 Yangco, Bienvenido G., 413  
 Yano, Kunichiro, 221  
 Yeung, Tin-Chuen, 65  
 Yoshinaga, Koji, 221  
 Yu, Victor L., 473  
 Zaffaroni, Giuseppe, 395  
 Zak, Oto, 311  
 Zimmermann, Willy, 735  
 Zissis, Nicholas P., 534  
 Zorzópulos, Jorge, 659  
 Zuromskis, Peter, 626  
 Zweig, Richard M., 16

## SUBJECT INDEX

### VOLUME 25

**AC-1370**  
 mechanism of action, 88  
 phagocyte functions, 88

**Acanthamoeba spp.**  
 phenothiazine compounds, 109

**Acridine orange**  
*K. pneumoniae* R plasmid deletion, 659

**Acyclic nucleosides**  
 9-(1,3-dihydroxy-2-propoxymethyl) guanine, 563

**Acyclovir**  
 antiviral-activity potentiation polyene macrolides, 772  
 efficacy, 10  
 herpes simplex virus, 10  
     DNA fragment synthesis, 507  
     patient-initiated treatment, 553

penetration, 10  
 synergy with interferon, 515  
 topical therapy, 10  
 varicella-zoster virus, 515

**Adenine arabinoside**  
 synergy with interferon, 515  
 varicella-zoster virus, 515

**Aerobic bacteria**  
 erythromycin, 529  
 RU 28965, 529

**Amikacin**  
 combinations  
     ceftazidime, 725  
     ceftizoxime, 725  
     ceftriaxone, 725  
     cystic fibrosis, 279  
     *P. aeruginosa*, 279  
     *P. cepacia*, 279

**Enterobacteriaceae**, 725

nephrotoxicity, 168

neutropenic-site rabbit model, 545

*P. aeruginosa*, 545  
 tubular reabsorption, 168

**Aminoglycosides**  
 combinations  
     teichomycin, 411  
     vancomycin, 411  
 enterococci, 411  
 extraction from renal cortical tissue, 783  
 modification by enzymes  
     *S. aureus*, 754  
     *S. epidermidis*, 754  
 nephrotoxicity, 168  
 2'-O-nucleotidyltransferase activity, 234

*P. aeruginosa*, 488, 534  
 rat tissue  
     enzyme immunoassays, 497  
 resistance, 234  
 staphylococci, 411  
 synergy with  $\beta$ -lactams, 534  
 tubular reabsorption, 168

**Amoxicillin**  
 combined with clavulanic acid, 276  
 urinary tract infections, 276, 626

**Amphotericin B**  
 antifungal activity, 387  
*Aspergillus* spp., 560  
*C. albicans* infection, 366  
 combinations  
     antifungal agents, 560  
     rifampin, 560  
 leishmaniasis, 655  
 liposome encapsulated, 366, 387, 655  
 prophylaxis, 366

**Ampicillin**  
 combinations  
     gentamicin, 408  
 comparative efficacy  
     pivmecillinam, 643  
*S. faecalis* endocarditis, 408  
 shigellosis, 643

**Anaerobic bacteria**  
*apalillin*, 162  
 cefoxitin, 764  
 cefpiramide, 162  
 ciprofloxacin, 342  
 clindamycin, 764  
 erythromycin, 529  
 metronidazole, 764  
 RU 28965, 529

**Animal viruses**  
 halothane, 719  
 replication, 719

**Antifungal agents**  
*Aspergillus* spp., 560  
 combinations  
     amphotericin B, 560  
     rifampin, 560

**Antifungal azoles**  
 Bay I 9139, 339  
 Bay n 7133, 339

**Antineoplastic agents**  
 screening  
     *E. coli* genetically modified strain, 622

**Antiviral compounds**  
 varicella-zoster virus susceptibility, 417

**Apalillin**  
 anaerobes, 162  
 comparative activity, 162  
     carbenicillin, 669  
     piperacillin, 669  
 pharmacokinetics  
     compared with piperacillin, 105

**1- $\beta$ -D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil**  
 varicella-zoster virus, 742

**Arsenate**  
*E. coli* R factors, 157

**Aspergillus** spp.  
 amphotericin B, 560  
 antifungal agents, 560  
 rifampin, 560

**Azlocillin**  
 comparative efficacy, 49  
 neutropenic-site rabbit model, 545

**P. aeruginosa**  
 drug combinations, 545  
 pneumonia, 49  
 pharmacokinetics  
     cystic fibrosis, 630

**Aztreonam**  
 activity  
     alone, 212  
     in combination, 212  
 biliary tract disease, 358  
 combinations  
     amikacin, 279  
     cystic fibrosis, 279  
     gram-negative bacilli, 283  
      $\beta$ -lactams, 283  
     multiple resistance, 283  
     *P. aeruginosa*, 279  
     *P. cepacia*, 279  
 comparative efficacy, 49  
 excretion, 358

immunology, 93  
*P. aeruginosa* pneumonia, 49  
 pediatric patients, 212  
 syphilis, 390

**Bacillus megaterium**  
 copper toxicity, 650  
 siderophores, 650

**Bacitracin**  
 coagulase-negative staphylococci, 502  
*S. aureus* nasal carriers, 422

**Bacterial infections**  
 cefmenoxime, 510

**Bacteriocins**  
*B. fragilis*, 253

**Bacteroides fragilis**  
 bacteriocins, 253  
 cephalosporins  
     7 $\alpha$ -methoxy, 131  
     7 $\beta$ -methoxyiminoacetamido, 131  
 clavulanic acid, 662  
 $\beta$ -lactams, 662  
 synergy with gentamicin  
     clindamycin, 71  
     metronidazole, 71  
     penicillin, 71

**Bacteroides melaninogenicus**  
 synergy with gentamicin  
     clindamycin, 71  
     metronidazole, 71  
     penicillin, 71

**Basidiobolus** spp.  
 susceptibility, 413

Bay I 9139  
 antifungal activity, 339

Bay n 7133  
 antifungal activity, 339  
 high-pressure liquid chromatography, 596

Bay o 9867  
 see ciprofloxacin

**Benzylpenicillin**  
 probenecid interaction, 676

**Biliary tract disease**  
 aztreonam excretion, 358

**Biophotometric methods**  
*S. aureus* intraphagocytic activity, 735

**Bordetella pertussis**  
 degraded strains, 537  
 resistance, 537

**Bromovinyl deoxyuridine**  
 synergy with interferon, 515  
 varicella-zoster virus, 515

(E)-5-(2-Bromovinyl)-2'-deoxyuridine  
 herpes simplex virus polypeptide synthesis, 566

**BW759U**  
 DNA polymerases  
     cellular  $\alpha$ , 191  
     herpes simplex virus induced, 191  
 triphosphate, 191

**Campylobacter fetus** subsp. *jejuni*  
 metronidazole, 145  
 niridazole, 145

**Campylobacter** spp.  
 ciprofloxacin, 504

**Candida albicans**  
 amphotericin B, 366

clotrimazole, 450  
 econazole, 450  
 growth, 483  
 ketoconazole, 281, 450  
 miconazole, 450  
 naftifine, 483  
 neutropenic mice, 366  
 sterol biosynthesis, 483  
 susceptibility  
     growth phase, 316  
     ketoconazole, 316  
     miconazole, 316  
 tioconazole, 450  
 vaginitis, 281

*Candida* spp.  
 peptide transport, 373  
 polyoxin, 373

Carbapenem derivatives  
 SF2103A, 348

Carbenicillin  
 comparative activity  
     apalcillin, 669  
     piperacillin, 669  
     hemostasis, 153

Cardiopulmonary bypass surgery  
 ceftriaxone levels, 37

Cefamandole  
 cross-resistance  
     methicillin, 666  
*E. coli*  
     killing, 182  
     phagocytosis, 182

Cefazolin  
 urinary excretion  
     furosemide, 618  
     piretanide, 618  
     water loading, 618

Cefmenoxime  
 serious bacterial infections, 510

Cefoperazone  
 penetration into surgical-wound drainage, 473

Ceforanide  
*S. aureus* endocarditis, 16

Cefotaxime  
 kinetics  
     effects of protein binding, 58  
 susceptibility, 377

Cefotiam  
 comparative efficacy  
     cephalothin, 778  
 dihydrochloride  
     placental transfer, 147  
 skin infections, 778  
 soft tissue infections, 778

Cefoxitin  
 anaerobic bacteria, 764  
 comparative activity  
     clindamycin, 764  
     metronidazole, 764  
 neutropenic-site rabbit model, 545  
*P. aeruginosa*, 545

Cefpiramide  
 anaerobes, 162  
 comparative activity, 162  
 pharmacokinetics  
     humans, 221

Cefsulodin  
 cystic fibrosis, 4  
*P. aeruginosa* mutants, 382  
 pharmacokinetics  
     cystic fibrosis, 579  
     single dose, 579

Ceftazidime  
 combinations  
     amikacin, 725  
     clindamycin, 657  
     gentamicin, 725  
 distribution in ascitic fluid, 760  
*Enterobacteriaceae*, 725  
*H. influenzae*, 29  
 meningitis  
     efficacy, 29  
     pharmacokinetics, 29  
 nephrotoxicity in rats, 513  
*P. aeruginosa* mutants, 382  
 pharmacokinetics  
     decreased renal function, 785  
     meningitis, 29  
     normal subjects, 638  
     renal insufficiency, 201  
     uremic subjects, 638  
*Pseudomonas* spp., 395  
 urinary tract infections, 395

Ceftizoxime  
 combinations  
     amikacin, 725  
     gentamicin, 725, 770  
*Enterobacteriaceae*, 725  
 high-pressure liquid chromatography, 336  
 meningitis, 258  
 neutropenic-site rabbit model, 545  
*P. aeruginosa*, 545, 770  
 uremic patients, 336

Ceftriaxone  
 amikacin, 725  
 combinations  
     gentamicin, 725  
*Enterobacteriaceae*, 725  
*H. influenzae*, 29  
 kinetic disposition  
     renal failure patients, 83  
 levels in blood and tissue  
     cardiopulmonary bypass surgery, 37  
 meningitis  
     efficacy, 29, 40  
 pharmacokinetics  
     meningitis, 29  
     renal impairment, 438

Cefuroxime  
 1-acetoxyethyl ester, 78  
 axetil  
     pharmacokinetics, 344  
 meningitis, 273

Cephalosporinases  
*P. maltophilia*, 362

Cephalosporins  
 aminothiazolyl  $\alpha$ -methoxyimino, 710  
*B. fragilis*, 131  
 cross-resistance  
     cefamandole, 666  
     methicillin, 666  
 expanded spectrum  
     SK&F 88070, 694  
 HR810, 710  
 7 $\alpha$ -methoxy, 131  
 7 $\beta$ -methoxyiminoacetamido, 131  
 resistance  
     *Citrobacter* spp., 591

Cephalothin  
 comparative efficacy  
     cefotiam, 778  
*Enterobacteriaceae* resistance, 725  
 skin infections, 778  
 soft tissue infections, 778

Cephems  
 FK 027, 98

Chancroid  
*H. ducreyi*, 187  
 tetracycline resistance, 187

*Chlamydia trachomatis*  
 cinoxacin, 123  
 ciprofloxacin, 123  
 nalidixic acid, 123  
 norfloxacin, 123  
 pipemidic acid, 123

Chloramphenicol  
 antagonism of  $\beta$ -lactams, 405  
 comparative activity, 327  
 detection, 205  
 enzyme-linked immunoassay, 205  
*K. pneumoniae*, 405  
 quantitation, 205  
*Salmonella* spp., 327

Chlorpromazine  
 hydrochloride  
     pathogenic amoebae, 109  
*L. donovani*, 571

Cinoxacin  
 antibacterial activity, 633  
 cross-resistance  
     DJ6783, 775  
     enoxacin, 775  
     nalidixic acid, 775  
     norfloxacin, 775  
     oxolinic acid, 775  
*C. trachomatis*, 123  
 resistant-population selection, 775

Ciprofloxacin  
 anaerobic bacteria, 342  
 antibacterial activity, 633  
*Campylobacter* spp., 504  
 comparative activity, 319, 331, 518  
*C. trachomatis*, 123  
 enteric pathogens, 504  
 inoculum effect, 342  
 medium effect, 342  
 pH effect, 342

*Citrobacter* spp.  
 cephalosporin resistance, 591

Clavulanic acid  
 combined with amoxicillin  
     urinary tract infections, 276  
 combined with ticarcillin, 392  
 $\beta$ -lactam activity, 662

Clindamycin  
 anaerobic bacteria, 764  
 combined with ceftazidime  
     antibacterial activity, 657  
 comparative activity  
     cefoxitin, 764  
 synergy  
     *Bacteroides* spp., 71  
     gentamicin, 71

Clotrimazole  
*C. albicans*, 450

Cloxacillin  
 staphylococcal endocarditis, 311

Common cold  
 zinc gluconate, 20

*Conidiobolus* spp.  
 susceptibility, 413

Contact-blocking virus inhibitor  
 size, 646  
 stability, 646

Copper  
*B. megaterium*, 560  
 toxicity

siderophores, 560

**Coumeyycin**  
antibacterial activity, 687

**Cystic fibrosis**  
amikacin, 279  
azlocillin pharmacokinetics, 630  
aztreonam, 279

**cefsulodin**  
pharmacokinetics, 579  
sodium, 4

*P. aeruginosa*, 279

*P. cepacia*, 279

piperacillin, 279

ticarcillin, 279

**Cytomegalovirus**  
 $\alpha$ -interferon, 25  
2'-nor-2'-deoxyguanosine, 247  
retinitis, 25

**Desferrioxamine**  
urinary tract isolates, 375

**cis-Diammineplatinum(II)-polyglutamic acid**  
*T. congolense*, 286

**Dibekacín**  
nephrotoxicity, 168  
tubular reabsorption, 168

**9-(1,3-Dihydroxy-2-propoxymethyl) guanine**  
herpes simplex virus, 563

$\beta$ -interferon, 563

**DJ6783**  
cross-resistance  
cinoxacin, 775  
enoxacin, 775  
nalidixic acid, 775  
norfloxacin, 775  
oxolinic acid, 775  
resistant-population selection, 775

**DNA gyrase inhibitors**  
*E. coli* plasmid elimination, 586

**DNA polymerases**  
BW759U triphosphate, 191  
cellular  $\alpha$ , 191  
hepatitis virus, 242  
herpes simplex virus induced, 191

**Doxycycline**  
polymorphonuclear leukocytes, 354

**Econazole**  
*C. albicans*, 450

**Endocarditis**  
ampicillin, 408  
cefazolin, 16  
cloxacillin, 311  
drug abusers, 16  
gentamicin, 408  
granulocutes, 263  
mezlocillin, 408  
*S. aureus*, 16  
*S. faecalis*, 408  
*S. sanguis*, 263  
staphylococcal, 311

**Enoxacin**  
cross-resistance  
cinoxacin, 775  
DJ6783, 775  
nalidixic acid, 775  
norfloxacin, 775  
oxolinic acid, 775  
resistant-population selection, 775

**Enteric pathogens**  
ciprofloxacin, 504

**Enterobacter aerogenes**  
endocarditis  
gentamicin, 683  
mezlocillin, 683  
ticarcillin, 683

**Enterobacteria**  
 $\beta$ -lactamases, 268

**Enterobacteriaceae**  
amikacin, 725  
ceftazidime, 725  
ceftizoxime, 725  
ceftriaxone, 725  
cephalothin resistant, 725  
gentamicin, 725

**Enterococci**  
aminoglycosides, 411  
ribosomal resistance, 398  
rifampin, 411  
streptomycin, 398  
susceptibility, 532  
teichomycin, 411  
vancomycin, 411

**Enzyme immunoassays**  
aminoglycosides  
rat tissue, 497

**Enzyme-linked immunoassays**  
competitive  
chloramphenicol, 205

**Enzymes**  
aminoglycoside modification, 754  
*S. aureus*, 754  
*S. epidermidis*, 754

**Erysipelas**  
swine  
*E. rhusiopathiae* resistance, 385

**Erysipelothrix rhusiopathiae**  
chronic swine erysipelas, 385  
resistance, 385

**Erythromycin**  
aerobic bacteria, 529  
anaerobic bacteria, 529  
comparative activity, 529  
methylmalonyl-coenzyme A source, 173  
synthesis from *S. erythreus*, 173

**Escherichia coli**  
cefamandole, 182  
DNA gyrase inhibitors, 586  
DNA repair mutants, 65  
genetically modified strain  
antineoplastic-agent screening, 622  
gentamicin, 182  
killing, 182

**meningitis**  
mezlocillin pharmacokinetics, 427  
metronidazole, 65  
novobiocin, 586  
outer membrane permeability, 539  
phagocytosis, 182  
plasmid elimination, 586  
pMG110, 586

**R factors**  
arsenate, 157  
homology, 157

**tetracyclines**, 539  
tetracycline transport, 446

**Exopolysaccharides**  
*P. aeruginosa*  
binding, 673

**FK 027**  
antibacterial properties, 98

**Fludalanine**  
pentazidone combination  
comparative activity, 612

**Flumequine**  
fluorometric assays, 301  
high-pressure liquid chromatography, 301  
microbiological assays, 301

**Fluorinated piperazinyl-substituted quinoline derivatives**  
comparative activity, 518

**Fluorometric assays**  
flumequine, 301

**Furosemide**  
cefazolin excretion in urine, 618

**Gentamicin**  
coagulase-negative staphylococci, 502  
combinations  
ampicillin, 408  
ceftazidime, 725  
ceftizoxime, 725, 770  
ceftriaxone, 725  
mezlocillin, 408

*E. coli*  
killing, 182  
phagocytosis, 182  
elimination rate, 128  
clearance, 128

**Enterobacteriaceae**, 725  
hemodialysis, 128  
nephrotoxicity, 168  
*P. aeruginosa*, 770  
synergy  
*B. fragilis*, 71  
*B. melaninogenicus*, 71  
clindamycin, 71  
metronidazole, 71  
penicillin, 71  
tubular reabsorption, 168

**Gonorrhea**  
rosoxacin, 455

**Gram-negative bacteria**  
aztreonam, 283  
 $\beta$ -lactams, 283  
multiple resistance, 283  
polymyxin B nonapeptide, 701

**Granulocytes**  
*S. sanguis* endocarditis, 263  
stimulation  
imipenem, 179  
MK 0791, 179

**Haemophilus ducreyi**  
chancroid treatment, 187  
 $\beta$ -lactamase plasmid, 296  
resistance  
plasmid mediated, 187  
tetracycline, 187

**Haemophilus influenzae**  
multiply resistant  
susceptibility, 706

**type b**  
ceftazidime, 29  
ceftriaxone, 29  
chloramphenicol resistant, 29  
imipenem, 29  
 $\beta$ -lactams, 747  
mechanisms of resistance, 747  
meningitis, 29

**Halothane**  
animal virus replication, 719

**Heavy-metal salts**  
 susceptibility  
*M. avium*, 137  
*M. intracellulare*, 137  
*M. scrofulaceum*, 137

**Hemodialysis**  
 gentamicin  
   clearance, 128  
   elimination rate, 128

tobramycin  
   clearance, 128  
   elimination rate, 128

**Hemostasis**  
 carbenicillin, 153  
 mezlocillin, 153  
 placebo, 153

**Hepatitis virus**  
 DNA polymerases, 242  
 human, 242  
 woodchuck, 242

**Herpes labialis**  
 acyclovir, 553  
 patient-initiated treatment, 553

**Herpes simplex virus**  
 acyclovir  
   DNA fragment synthesis, 507  
   efficacy, 10  
   penetration, 10  
   topical therapy, 10  
 $(E)$ -5-(2-bromovinyl)-2'-deoxyuridine, 566  
 BW759U triphosphate, 191  
 9-(1,3-dihydroxy-2-propoxymethyl) guanine, 563  
 DNA polymerase induction, 191  
 $\beta$ -interferon, 563  
 $(E)$ -5-(2-iodovinyl)-2'-deoxyuridine uptake, 476  
 lithium  
   cell cultures, 522  
   latent-infection reactivation in rabbits, 522  
 2'-nor-2'-deoxyguanosine, 238  
 orofacial infections in mice, 238  
 polypeptide synthesis, 566  
 SK&F 21681, 195  
 thymidine kinase  
   guanosine analogs, 524

**High-pressure liquid chromatography**  
 Bay n 7133, 596  
 ceftizoxime, 336  
 flumequine, 301  
 Sch 28191 levels, 45

**HR810**  
 evaluation, 710

**Hypoprothrombinemia**  
 1-methyl-5-thiotetrazole, 380  
 moxalactam, 380

**Imidazoles**  
*C. albicans*, 450  
 clotrimazole, 450  
 econazole, 450  
 ketoconazole, 450  
 miconazole, 450  
 tioconazole, 450

**Imipenem**  
 bioactivity  
   medium, 781  
   temperature, 781  
   time, 781  
 granulocyte function stimulation, 179

*H. influenzae*, 29  
 imipenem resistance, 491  
 meningitis  
   efficacy, 29  
   pharmacokinetics, 29

methicillin resistance  
*S. aureus*, 491  
*P. vulgaris*  $\beta$ -lactamase, 149  
 subinhibitory concentrations, 491

**Influenza virus**  
 inhibition  
   interferon, 53  
   ribavirin, 53  
   rimantadine hydrochloride, 53

**Inosine analogs**  
*Leishmania* spp., 292  
*Trypanosoma* spp., 292

**Interferon**  
 aerosolized, 729  
 clearance, 729  
 cytomegalovirus retinitis, 25  
 $9$ -(1,3-dihydroxy-2-propoxymethyl) guanine, 563  
 herpes simplex virus, 563  
 human leukocyte, 515  
 influenza virus inhibition, 53  
 pulmonary deposition, 729  
 synergy  
   acyclovir, 515  
   adenine arabinoside, 515  
   bromovinyl deoxyuridine, 515  
   phosphonoformic acid, 515

**Intraphagocytic activity**  
 biophotometric method, 735  
*S. aureus*, 735  
 $(E)$ -5-(2-iodovinyl)-2'-deoxyuridine  
 herpes simplex virus, 476  
 uptake, 476

**Kanamycin**  
 acetyltransferase  
   enzymatic modification, 479  
   resistance, 479  
    $V_{max}/K_m$  ratio, 479

**Ketoazole**  
*C. albicans*  
   growth phase, 316  
   inhibition, 450  
   killing, 450  
   susceptibility, 316  
   vaginitis, 281  
 pharmacokinetics  
   influence of food, 1

**Klebsiella pneumoniae**  
 chloramphenicol, 405  
 $\beta$ -lactams, 405  
 R plasmids  
   acridine orange, 659  
   deletions, 659

**$\beta$ -Lactamases**  
 enterobacteria, 268  
*H. ducreyi*, 296  
 inactivation, 348  
 mezlocillin-resistant *S. aureus*  
   cell bound, 125  
   extracellular, 125  
*N. gonorrhoeae*, 296  
*P. aeruginosa* mutants, 382  
 PSE-2, 268  
*P. vulgaris*  
   imipenem, 149

**SF2103A**, 348

**$\beta$ -Lactams**  
 antagonism by chloramphenicol, 405  
*B. fragilis*  
   clavulanic acid, 662  
 combinations  
   aztreonam, 283  
   gram-negative bacilli, 283  
   multiple resistance, 283

*H. influenzae* type b  
 mechanism of resistance, 747

*K. pneumoniae*, 405

*P. aeruginosa*, 488, 534  
 synergy with aminoglycosides, 534

temocillin combinations, 142

Lankacidin group antibiotics  
 side chain modifications, 226

*Leishmania donovani*  
 chlorpromazine, 571

**Leishmaniasis**  
 amphotericin B, 655

*Leishmania* spp.  
 inosine analogs, 292

**Listeria monocytogenes**  
 meningitis  
   mezlocillin pharmacokinetics, 427

**Lithium**  
 herpes simplex virus  
   cell cultures, 522  
   latent-infection reactivation in rabbits, 522

**Meningitis**  
 ceftazidime, 29  
 ceftizoxime, 258  
 ceftriaxone, 29, 40  
 cefuroxime, 273  
*E. coli*, 427  
 imipenem, 29  
*L. monocytogenes*, 427  
 mezlocillin pharmacokinetics, 427  
 traditional therapy, 40

**Methicillin**  
 cross-resistance  
   cefamandole, 666  
   cephalosporins, 666  
 resistance  
   imipenem, 491  
   *S. aureus*, 491

**Methylmalonyl-coenzyme A**  
 erythromycin synthesis, 173  
*S. erythreus*, 173

**1-Methyl-5-thiotetrazole**  
 hypoprothrombinemia, 380

**Metronidazole**  
 anaerobic bacteria, 764  
*C. fetus* subsp. *jejuni*, 145  
 comparative activity  
   cefoxitin, 764

*E. coli* DNA repair mutants, 65

pharmacokinetics  
   peritoneal dialysis patients, 306

synergy  
   *Bacteroides* spp., 71

gentamicin, 71

**Mezlocillin**  
 combinations  
   gentamicin, 408, 683

*E. aerogenes* endocarditis, 683

*E. coli*, 427

hemostasis, 153

*L. monocytogenes*, 427  
 pharmacokinetics  
     meningitis, 427  
     newborn infants, 556  
     pediatric oncology patients, 62  
*S. aureus* resistance  
      $\beta$ -lactamase, 125  
*S. faecalis* endocarditis, 408  
**Miconazole**  
     *C. albicans*  
         growth phase, 316  
         inhibition, 450  
         killing, 450  
         susceptibility, 316  
 Microbiological assays  
     flumequine, 301  
**Minocycline**  
     polymorphonuclear leukocytes, 354  
**MK 0791**  
     granulocyte function stimulation, 179  
**Moxalactam**  
     hypoprothrombinemia, 380  
 pharmacokinetics  
     elderly subjects, 33  
**Mycobacterium avium**  
     susceptibility  
         heavy-metal salts, 137  
         oxyanions, 137  
**Mycobacterium intracellulare**  
     susceptibility  
         heavy-metal salts, 137  
         oxyanions, 137  
**Mycobacterium scrofulaceum**  
     susceptibility  
         heavy-metal salts, 137  
         oxyanions, 137

*Naegleria fowleri*  
     phenothiazone compounds, 109  
**Nafifine**  
     *C. albicans*, 483  
**Nalidixic acid**  
     antibacterial activity, 633  
     cross-resistance  
         cinoxacin, 775  
         DJ6783, 775  
         enoxacin, 775  
         norfloxacin, 775  
         oxolinic acid, 775  
*C. trachomatis*, 123  
     resistant-population selection, 775

*Neisseria gonorrhoeae*  
     envelope mutations  
         antibiotic susceptibility, 767  
         env-10, 767  
         pyocin resistance, 767  
      $\beta$ -lactamase plasmid, 296  
     probencid, 676  
     resistance trends, 7  
**Neisseria meningitidis**  
     nasopharyngeal carriers, 494  
     Sch 29, 482, 494  
**Nephrototoxicity**  
     aminoglycosides, 168  
     tubular reabsorption, 168  
**Netilmicin**  
     nephrototoxicity, 168  
     tubular reabsorption, 168  
**Niridazole**  
     *C. fetus* subsp. *jejuni*, 145  
**Nocardia asteroides**  
     susceptibility, 165

**Nocardicin A**  
     synergy  
         L-norvalyl-L-1-aminoethylphosphonic acid, 105  
**2'-Nor-2'-deoxyguanosine**  
     cytomegalovirus, 247  
     herpes simplex virus, 238  
**Norfloxacin**  
     antibacterial activity, 633  
     cross-resistance  
         cinoxacin, 775  
         DJ6783, 775  
         enoxacin, 775  
         nalidixic acid, 775  
         oxolinic acid, 775  
*C. trachomatis*, 123  
     resistant-population selection, 775  
**L-Norvalyl-L-1-aminoethylphosphonic acid**  
     synergy  
         nocardicin A, 607  
**Novobiocin**  
     *E. coli* plasmid elimination, 586  
**2'-O-Nucleotidyltransferase**  
     activity-aminoglycoside resistance relation, 234

**Oleandomycin**  
     derivatives  
         biological activity, 113, 118  
         synthesis, 113  
**Osteomyelitis**  
     vancomycin  
         concentrations in rabbit serum, 140  
**Oxacillin**  
     coagulase-negative staphylococci, 502  
**Oxolinic acid**  
     antibacterial activity, 633  
     cross-resistance  
         cinoxacin, 775  
         DJ6783, 775  
         enoxacin, 775  
         nalidixic acid, 775  
         norfloxacin, 775  
     resistant-population selection, 775

**Oxyanions**  
     susceptibility  
         *M. avium*, 137  
         *M. intracellulare*, 137  
         *M. scrofulaceum*, 137  
**Oxypertetracycline**  
     polymorphonuclear leukocytes, 354

**Pediatric patients**  
     aztreonam activity, 212  
**Pefloxacin mesylate**  
     absorption, 463  
     distribution, 463  
     elimination, 463  
     metabolic fate, 463  
**Penicillin**  
     synergy  
         *Bacteroides* spp., 71  
         gentamicin, 71  
**Pentizidone**  
     fludalanine combination  
         comparative activity, 612  
**Pharmacokinetics**  
     apalcillin, 105  
     azlocillin, 607  
     cepiramide, 221  
     cefusulodin, 579

**ceftazidime**  
     decreased renal function, 785  
*H. influenzae* meningitis, 29  
 normal subjects, 638  
 renal insufficiency, 201  
 uremic subjects, 638  
**Ceftriaxone**  
     *H. influenzae* meningitis, 29  
     renal impairment, 438  
**Cefuroxime axetil**, 344  
**Imipenem**, 29  
**Ketoconazole**, 1  
**Metronidazole**, 306  
**mezlocillin**  
     meningitis, 427  
     newborn infants, 556  
     pediatric oncology patients, 62  
**Moxalactam**, 33  
**Piperacillin**, 105  
**Sultamicillin**, 599  
**Vancomycin**  
     peritoneal dialysis, 603  
     renal insufficiency, 433  
**Phenothiazone compounds**  
     chlorpromazine hydrochloride, 109  
     inhibition of pathogenic amoebae, 109  
     trifluoperazine dihydrochloride, 109  
**Phosphomycin**  
     pleural effusion patients, 458  
**Phosphonoformic acid**  
     synergy with interferon, 515  
     varicella-zoster virus, 515  
**Pipemidic acid**  
     *C. trachomatis*, 123  
**Piperacillin**  
     combinations  
         amikacin, 279  
         cystic fibrosis, 279  
         *P. aeruginosa*, 279  
         *P. cepacia*, 279  
     comparative activity  
         apalcillin, 669  
         carbenicillin, 669  
     comparative efficacy, 49  
     *P. aeruginosa*  
         mutants, 382  
         pneumonia, 49  
     pharmacokinetics  
         compared with apalcillin, 105  
     susceptibility, 377  
**Piretanide**  
     cefazoline excretion in humans, 618  
**Pivmecillinam**  
     comparative efficacy  
         ampicillin, 643  
         shigellosis, 643  
**Placebo**  
     hemostasis, 153  
**Plasmids**  
     DNA gyrase inhibitors, 586  
     *E. coli*(pMG110), 586  
     novobiocin, 586  
     resistance  
         acridine orange, 659  
         deletions, 659  
         host range, 289  
         *K. pneumoniae*, 659  
         streptococcal macrolide, 289  
     *S. wien* epidemic history, 499  
**Pleural effusion**  
     phosphomycin, 458  
**Pneumonia**  
     azlocillin, 49

aztreonam, 49  
*P. aeruginosa*, 49  
 piperacillin, 49  
 ticarcillin, 49  
 tobramycin, 49  
**Polyene macrolides**  
 acyclovir activity, 772  
**Polymorphonuclear leukocytes**  
 doxycycline, 354  
 minocycline, 354  
 oxytetracycline, 354  
**Polymyxin B nonapeptide**  
 gram-negative bacteria, 701  
**Polyoxin**  
 anti-*Candida* activity, 373  
 peptide transport, 373  
**Probenecid**  
 benzylpenicillin interaction, 676  
*N. gonorrhoeae*, 676  
**Protease inhibitors**  
 amidine type, 582  
*R. rickettsii*, 582  
**Protein binding**  
 cefotaxime kinetics, 58  
**Proteus vulgaris**  
 $\beta$ -lactamase  
 imipenem, 149  
**Pseudomonas aeruginosa**  
 amikacin, 279, 545  
 aminoglycosides, 488, 534  
 azlocillin, 49, 545  
 aztreonam, 49, 279  
 cefoxitin, 545  
 cefsulodin, 382  
 ceftazidime, 382  
 ceftizoxime, 545, 770  
 cystic fibrosis, 279  
 exopolysaccharide  
 binding, 673  
 gentamicin, 770  
 $\beta$ -lactamase, 382  
 $\beta$ -lactams, 488, 534  
 mutants, 382  
 neutropenic-site rabbit model, 545  
 piperacillin, 49, 279, 382  
 pneumonia, 49  
 ticarcillin, 49, 279  
 tobramycin, 49  
**Pseudomonas cepacia**  
 amikacin, 279  
 aztreonam, 279  
 cystic fibrosis, 279  
 piperacillin, 279  
 ticarcillin, 279  
**Pseudomonas maltophilia**  
 cephalosporinase, 362  
**Pseudomonas spp.**  
 ceftazidime, 395  
 urinary tract infections, 395  
**Pyocins**  
*N. gonorrhoeae* resistance, 767  
  
**Quinolone carboxylic acid compounds**  
 ciprofloxacin, 319, 331  
  
**Renal enzyme inhibitors**  
 MK 0791, 179  
**Renal insufficiency**  
**pharmacokinetics**  
 ceftazidime, 201  
 ceftriaxone, 438  
 vancomycin, 433  
  
**Resistance**  
*N. gonorrhoeae*, 7  
**Retinitis**  
 cytomegalovirus, 25  
 $\alpha$ -interferon, 25  
**R factors**  
*E. coli*  
 arsenate, 157  
 homology, 157  
**Ribavirin**  
 influenza virus inhibition, 53  
**Rickettsia rickettsii**  
 cell injury, 582  
 protease inhibitors, 582  
**Rifampin**  
*Aspergillus* spp., 560  
 combinations  
 amphotericin B, 560  
 antifungal agents, 560  
 teichomycin, 411  
 vancomycin, 411  
 enterococci, 411  
*S. aureus* nasal carriers, 422  
 staphylococci, 411  
**Rimantadine hydrochloride**  
 influenza virus inhibition, 53  
**Rochalimaea quintana**  
 susceptibility patterns, 690  
 trench fever, 690  
**Roxoxacin**  
*gonorhoea*, 455  
**RU 28965**  
 aerobic bacteria, 529  
 anaerobic bacteria, 529  
 comparative activity, 529  
  
**Salmonella** spp.  
 chloramphenicol, 327  
**Salmonella wien**  
 epidemic history, 499  
 plasmid stability, 499  
**Sch 28191**  
 high-pressure liquid chromatography, 45  
 levels in biological fluids, 45  
**Sch 29,482**  
*N. meningitidis* nasopharyngeal carriers, 494  
**SF2103A**  
 $\beta$ -lactamase inactivation, 348  
**Shigella flexneri**  
 sulfamethoxazole-trimethoprim resistance, 653  
**Shigellosis**  
 ampicillin, 643  
 pivmecillinam, 643  
**Siderophores**  
*B. megaterium*, 560  
 copper toxicity enhancement, 560  
**SK&F 21681**  
 herpes simplex virus, 191  
**SK&F 88070**  
 antimicrobial activity, 694  
**Skin infections**  
 cefotiam, 778  
 cephalothin, 778  
**SM-1652**  
 see cefpiramide  
**Soft tissue infections**  
 cefotiam, 778  
 cephalothin, 778  
  
**Sparsomycin**  
 nontoxic analogs  
 hydrophobic sulfoxide substituent, 443  
 puromycin, 443  
**Staphylococci**  
 aminoglycosides, 411  
 cloxacillin, 311  
 coagulase negative  
 bacitracin, 502  
 gentamicin, 502  
 oxacillin, 502  
 streptomycin, 502  
 vancomycin, 502  
 endocarditis, 311  
 rifampin, 411  
 teichomycin, 411  
 vancomycin, 411  
**Staphylococcus aureus**  
 aminoglycoside-modifying enzyme, 754  
 biophotometric method, 735  
 ceforanide, 16  
 endocarditis, 16  
 intraphagocytic activity, 735  
 mezlocillin resistance  
 $\beta$ -lactamase, 125  
 nasal carriers  
 bacitracin, 422  
 rifampin, 422  
**resistance**  
 imipenem, 491  
 methicillin, 491  
 tolerance detection, 571  
**Staphylococcus epidermidis**  
 aminoglycoside-modifying enzyme, 754  
**Streptococci**  
 resistance plasmids, 289  
**Streptococcus faecalis**  
 ampicillin, 408  
 gentamicin, 408  
 endocarditis, 408  
 mezlocillin, 408  
**Streptococcus sanguis**  
 endocarditis, 263  
 granulocytes, 263  
 vancomycin resistance, 527  
**Streptomyces erythreus**  
 erythromycin synthesis, 173  
 methylmalonyl-coenzyme A, 173  
**Streptomyces fradiae**  
 carbon incorporation  
 tylactone, 216  
**Streptomycin**  
 coagulase-negative staphylococci, 502  
 enterococci, 398  
 ribosomal resistance, 398  
**Sulfamethoxazole**  
 combined with trimethoprim, 653  
**Sulfamethoxazole-trimethoprim**  
*S. flexneri* resistance, 653  
**Sultamicillin**  
 pharmacokinetics, 599  
**Surgical wounds**  
 cefoperazone penetration, 473  
**Syphilis**  
 aztreonam, 390  
  
**Teichomycin**  
 combinations  
 aminoglycosides, 411  
 rifampin, 411  
 enterococci, 411  
 staphylococci, 411

**Temocillin**  
combined with other  $\beta$ -lactams, 142  
**Tetracyclines**  
chancre treatment, 187  
doxycycline, 354  
*E. coli* outer membrane permeability, 539  
*H. ducreyi* resistance, 187  
hydrophobicity, 539  
minocycline, 354  
oxytetracycline, 354  
polymorphonuclear leukocytes, 354  
transport into *E. coli*, 446  
**Ticarcillin**  
combinations  
amikacin, 279  
clavulanic acid, 392  
cystic fibrosis, 279  
gentamicin, 683  
*P. aeruginosa*, 279  
*P. cepacia*, 279  
comparative efficacy, 49  
*E. aerogenes* endocarditis, 683  
*P. aeruginosa* pneumonia, 49  
**Tioconazole**  
*C. albicans*, 450  
**Tobramycin**  
clearance, 128  
comparative efficacy, 49  
elimination rate, 128  
hemodialysis, 128  
*P. aeruginosa* pneumonia, 49  
susceptibility, 377

**Trench fever**  
*R. quintana*  
susceptibility patterns, 690  
**Trifluoperazine dihydrochloride**  
pathogenic amoebae, 109  
**Trimethoprim**  
combined with sulfamethoxazole, 653  
**Trypanosoma congoense**  
*cis*-diammineplatinum(II)-poly-glutamic acid, 286  
**Trypanosoma spp.**  
inosine analogs, 292  
**Tuftsin**  
analogs, 134  
antibacterial properties, 134  
**Tylactone**  
carbon incorporation  
amino acid derived, 216  
*S. fradiae*, 216  
**U-63196E**  
comparative activity, 401  
**Urinary tract infections**  
amoxicillin, 626  
amoxicillin-clavulanic acid, 276  
ceftazidime, 395  
desferrioxamine, 375  
*Pseudomonas* spp., 395  
**Vaginitis**  
*C. albicans*, 281  
ketoconazole, 281

**Vancomycin**  
coagulase-negative staphylococci, 502  
combinations  
aminoglycosides, 411  
rifampin, 411  
enterococci, 411  
osteomyelitis  
concentrations in rabbit serum, 140  
pharmacokinetics  
peritoneal dialysis, 603  
renal insufficiency, 433  
*S. sanguis* resistance, 527  
staphylococci, 411  
**Varicella-zoster virus**  
acyclovir, 515  
adenine arabinoside, 515  
1- $\beta$ -D-arabinofuranosyl-E-5-(2-bromo-vinyl)uracil, 742  
bromovinyl deoxyuridine, 515  
interferon, 515  
phosphonoformic acid, 515  
susceptibility, 417

**WIN 49375**  
susceptibility, 377

**Zinc gluconate**  
common cold, 20  
double-blind study, 20

